Onconetix Inc
ONCO
Company Profile
Business description
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
Contact
201 East Fifth Street
Suite 1900
CincinnatiOH45202
USAT: +1 513 620-4101
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
5
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,830.40 | 52.50 | 0.60% |
| CAC 40 | 7,878.46 | 111.75 | 1.44% |
| DAX 40 | 24,549.56 | 342.65 | 1.42% |
| Dow JONES (US) | 44,458.30 | 217.54 | 0.49% |
| FTSE 100 | 8,867.02 | 12.84 | 0.15% |
| HKSE | 23,923.07 | 30.75 | 0.13% |
| NASDAQ | 20,611.34 | 192.87 | 0.94% |
| Nikkei 225 | 39,610.61 | 210.67 | -0.53% |
| NZX 50 Index | 12,741.08 | 27.53 | -0.22% |
| S&P 500 | 6,263.26 | 37.74 | 0.61% |
| S&P/ASX 200 | 8,594.00 | 55.40 | 0.65% |
| SSE Composite Index | 3,504.35 | 11.30 | 0.32% |